Tweets
Wouldn’t it be great to be able to predict which women with RA would improve during pregnancy, & which would worsen? We’d be able to adjust DMARDs accordingly.
Gene expression signatures might tell us more - one key cluster here was 21x predictive.
#ACR23 ABST2481 @RheumNow https://t.co/OiDV5sUiYC
David Liew @drdavidliew ( View Tweet )
2 years 7 months ago
#ACR23 Abstr# 2488 Phase 2 RCT #SLE showed more patients on ABBV-599 HD (elsubrutinib (BTK-i) + UPA (JAK-i)) and UPA monotherapy met primary & secondary endpoints vs PBO at WK48W. No major malignancy/VTE concerns. No added superiority by adding BTK-i vs UPA alone @RheumNow https://t.co/MUN2o75gEE
Md Yuzaiful Md Yusof ( View Tweet )
2 years 7 months ago
During "Rashes in Rheumatology talk at #ACR23, Dr. Katherine Shaw does not routinely use HCQ for DM skin manifestations.
⭐️Only ~10% of DM patients respond to monotherapy with HCQ but potential increased risk of hypersensitivity, especially in MDA5-DM
➡️Suspect that slight HCQ… https://t.co/aRmFmzuAum
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 7 months ago
HCQ and risk of retinopathy 👁️
DoD database HCQ 44000+ females & 10000+ males
Risk retinopathy HR 1.5
Variations according to diagnosis SLE higher risk vs. RA, more so in males HR 2, females HR 1.7
No adjustment on HCQ dose
@RheumNow #ACR23 ABST2452 https://t.co/TtTu6ixb45
Aurelie Najm ( View Tweet )
2 years 7 months ago
@md_chawla @RheumNow https://t.co/PVxox5t8ZH
Links:
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 7 months ago
@md_chawla @RheumNow https://t.co/qSdT7by1Vh
Links:
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
2 years 7 months ago
Erosive hand #OA may be more painful than treated #RA patients. The burden of OA is often not alked about, and this study highlights it! @RheumNow #ACR23 https://t.co/jLbvtMmgE0
Bella Mehta @bella_mehta ( View Tweet )
2 years 7 months ago
#ACR23 Abstr# 2489 I can’t wait for Phase 3 RCT results as I have many #SLE patients with refractory cutaneous lupus. Post-hoc analyses of Phase 2 RCT of Deucravacitinib showed its efficacy (CLASI-50) over PBO across all CLE subtypes @RheumNow https://t.co/G7edkAU18J
Md Yuzaiful Md Yusof ( View Tweet )
2 years 7 months ago
And to continue
B-SAFE Clinical risk score for HCQ retinopathy 👁️ 10 years
4000+ pts, 3% retinopathy over 5yrs
Predictors of HCQ retinopathy
-body weight
-sex
-age
-eGFR
-weight based dose mg/kg
-higher cumulative dose
Risk ranges 1% to >20%
@RheumNow #ACR23 ABST2453 https://t.co/h2tl6vH9M3 https://t.co/8iuRxoVaJ0
Aurelie Najm ( View Tweet )
2 years 7 months ago
Very nice to meet @KDAO2011 and @uptoTate as the faculty of Rheum Now @RheumNow tune in, follow them and listen to their interviews on the latest updates from #ACR23 https://t.co/I30wdVoqbd
Dr. Antoni Chan ( View Tweet )
2 years 7 months ago
Synovitis in hand #OA
genetic
risk of synovitis predisposed to clinical and radiographic hand OA
@RheumNow #ACR23 https://t.co/aXnXD7UPnv
Bella Mehta @bella_mehta ( View Tweet )
2 years 7 months ago
Rheumatologist - pharmacist co-management of MTX initiators @GeisingerHealth Philadelphia
Having the dual skill set actually helped with adherence to guidelines vs standard care. Would be great to see how this works with implementation in RA clinics
#ACR23 ABST2484 @RheumNow https://t.co/88R1BYzYn5
David Liew @drdavidliew ( View Tweet )
2 years 7 months ago
